Outlook Therapeutics (OTLK) Operating Income (2015 - 2026)
Outlook Therapeutics (OTLK) reported Operating Income of -$14.0 million for Q1 2026, down 13.2% year-over-year from -$16.2 million in Q1 2025, and down 4.03% quarter-over-quarter from -$13.5 million in Q4 2025.
Outlook Therapeutics (OTLK) Operating Income (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Operating Income data on file, last reported at -$14.0 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$14.0 million, down 13.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$60.6 million (up 20.75% YoY), and the FY2025 annual result was -$67.1 million, up 6.47% from the prior year.
- Operating Income retreated to -$14.0 million in Q1 2026 per OTLK's latest filing, from -$13.5 million in the prior quarter.
- Over five years, Operating Income peaked at -$6.8 million in Q1 2023 and troughed at -$22.9 million in Q3 2024.
- A 5-year average of -$15.8 million and a median of -$15.7 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income jumped 63.84% in 2023, then tumbled 176.98% in 2024.
- A 5-year view of Operating Income shows it stood at -$15.7 million in 2022, then surged by 34.2% to -$10.3 million in 2023, then tumbled by 109.31% to -$21.6 million in 2024, then surged by 37.59% to -$13.5 million in 2025, then decreased by 4.03% to -$14.0 million in 2026.
- Business Quant data shows OTLK's Operating Income at -$14.0 million in Q1 2026, -$13.5 million in Q4 2025, and -$17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -65.83 Mn |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | -14.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.03 Mn |
| Dec 31, 2025 | -13.48 Mn |
| Sep 30, 2025 | -17.31 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Mar 31, 2025 | -12.39 Mn |
| Dec 31, 2024 | -21.61 Mn |
| Sep 30, 2024 | -22.88 Mn |
| Jun 30, 2024 | -19.56 Mn |
| Mar 31, 2024 | -18.94 Mn |
| Dec 31, 2023 | -10.32 Mn |
| Sep 30, 2023 | -12.46 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -13.99 Mn |
| Jun 30, 2022 | -17.02 Mn |
| Mar 31, 2022 | -18.91 Mn |
| Dec 31, 2021 | -13.15 Mn |
| Sep 30, 2021 | -13.44 Mn |
| Jun 30, 2021 | -11.47 Mn |